Abstract

The current state of knowledge about the role of high density lipoproteins (HDL) indicates that their anti-atherogenic function is mainly related to the effectiveness of their actions (mostly to the participation in reverse cholesterol transport from tissues to liver) rather than the concentration of HDL itself. HDLs are highly heterogeneous in their structure, lipid and protein composition and metabolic pathways and individual HDL subpopulations differ in their biological activity and effectiveness of anti-atherogenic actions. Apolipoproteins play a key role in HDL metabolism, therefore their presence in lipoproteins is one of the main criterion for HDL classification. According to this criterion HDLs containing apolipoprotein E, called HDL-apoE, are distinguished. Although the anti-atherogenic role of apo E has been demonstrated in many scientific reports, understanding of the mechanisms of formation, transformation and the role of HDL-apoE is still the aim of intense research. The results of epidemiological studies are inconclusive; some of them have demonstrated that high HDL- -apoE concentration has been associated with lower risk of developing coronary heart disease (CHD), while other studies have shown that high levels of HDL-apoE has been an independent risk factor for cardiovascular events and positively correlated with other risk factors for CHD.

References

• 1. Angeloni E., Paneni F., Landmesser U., Benedetto U., Melina G.,Lüscher T.F., Volpe M., Sinatra R., Cosentino F.: Lack of protectiverole of HDL-C in patients with coronary artery disease undergoingelective coronary artery bypass grafting. Eur. Heart J., 2013;34: 3557-3562
  Google Scholar
• 2. Bach-Ngohou K., Ouguerram K., Nazih H., Maugere P., RipollesPiquerB., Zair Y., Frenais R., Krempf M., Bard J.M.: ApolipoproteinE kinetics: influence of insulin resistance and type 2 diabetes. Int. J.Obes. Relat. Metab. Disord., 2002; 26: 1451-1458
  Google Scholar
• 3. Barbagallo C.M., Rizzo M., Noto D., Frasheri A., Pernice V., RubinoA., Pieri D., Pinto V., Cefalu A.B., Giordano C., Notarbartolo A.,Averna M.R.: Accumulation of apoE-enriched triglyceride-rich lipoproteinsin patients with coronary artery disease. Metabolism,2006; 55: 662-668
  Google Scholar
• 4. Boisvert W.A., Spangenberg J., Curtiss L.K.: Treatment of severehypercholesterolemia in apolipoprotein E-deficient mice by bonemarrow transplantation. J. Clin. Invest., 1995; 96: 1118-1124
  Google Scholar
• 5. Cohn J.S., Tremblay M., Amiot M., Bouthillier D., Roy M., GenestJ.Jr., Davignon J.: Plasma concentration of apolipoprotein E in intermediate-sizedremnant-like lipoproteins in normolipidemic and hyperlipidemicsubjects. Arterioscler. Thromb. Vasc. Biol., 1996; 16: 149-159
  Google Scholar
• 6. Cohn J.S., Tremblay M., Batal R., Jacques H., Veilleux L., RodriguezC., Barrett P.H., Dubreuil D., Roy M., Bernier L., Mamer O., Davignon J.: Effect of atorvastatin on plasma apoE metabolism in patients withcombined hyperlipidemia. J. Lipid Res., 2002; 43: 1464-1471
  Google Scholar
• 7. Davignon J., Cohn J.S., Mabile L., Bernier L.: Apolipoprotein E andatherosclerosis: insight from animal and human studies. Clin. Chim.Acta, 1999; 286: 115-143
  Google Scholar
• 8. Eren E., Yilmaz N., Aydin O.: High density lipoprotein and it’sdysfunction. Open Biochem. J., 2012; 6: 78-93
  Google Scholar
• 9. Faxon D.P., Creager M.A., Smith S.C.Jr., Pasternak R.C., Olin J.W.,Bettmann M.A., Criqui M.H., Milani R.V., Loscalzo J., Kaufman J.A.,Jones D.W., Pearce W.H.: Atherosclerotic vascular disease conference:executive summary: atherosclerotic vascular disease conference proceedingfor healthcare professionals from a special writing group ofthe American Heart Association. Circulation, 2004; 109: 2595-2604
  Google Scholar
• 10. Fielding J.C.: High-density lipoproteins: from basic biology toclinical aspects. John Wiley & Sons, Weinheim (Niemcy) 2007
  Google Scholar
• 11. Genest J.J.Jr., Bard J.M., Fruchart J.C., Ordovas J.M., Wilson P.F.,Schaefer E.J.: Plasma apolipoprotein A-I, A-II, B, E and C-III containingparticles in men with premature coronary artery disease. Atherosclerosis,1991; 90: 149-157
  Google Scholar
• 12. Greenow K., Pearce N.J., Ramji D.P.: The key role of apolipoproteinE in atherosclerosis. J. Mol. Med., 2005; 83: 329-342
  Google Scholar
• 13. Hannuksela M.L., Brousseau M.E., Meyn S.M., Nazih H., Bader G.,Shamburek R.D., Alaupovic P., Brewer H.B.Jr.: In vivo metabolism ofapolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:AIIand LpE:A-I:A-II. Atherosclerosis, 2002; 165: 205-220
  Google Scholar
• 14. Harris J.D., Schepelmann S., Athanasopoulos T., Graham I.R.,Stannard A.K., Mohri Z., Hill V., Hassall D.G., Owen J.S., Dickson G.:Inhibition of atherosclerosis in apolipoprotein-E-deficient mice followingmuscle transduction with adeno-associated virus vectors encodinghuman apolipoprotein-E. Gene Ther., 2002; 9: 21-29
  Google Scholar
• 15. Hatters D.M., Peters-Libeu C.A., Weisgraber K.H.: ApolipoproteinE structure: insights into function. Trends Biochem. Sci., 2006;31: 445-454
  Google Scholar
• 16. Hayek T., Oiknine J., Brook J.G., Aviram M.: Role of HDL apolipoproteinE in cellular cholesterol efflux: studies in apo E knockouttransgenic mice. Biochem. Biophys. Res. Commun., 1994; 205:1072-1078
  Google Scholar
• 17. Huang Y., von Eckardstein A., Wu S., Assmann G.: Effects ofthe apolipoprotein E polymorphism on uptake and transfer of cellderivedcholesterol in plasma. J. Clin. Invest., 1995; 96: 2693-2701
  Google Scholar
• 18. Huang Y., von Eckardstein A., Wu S., Maeda N., Assmann G.:A plasma lipoprotein containing only apolipoprotein E and with γmobility on electrophoresis releases cholesterol from cells. Proc.Natl. Acad. Sci. USA, 1994; 91: 1834-1838
  Google Scholar
• 19. Ishiguro H., Yoshida H., Major A.S., Zhu T., Babaev V.R., LintonM.F., Fazio S.: Retrovirus-mediated expression of apolipoproteinA-I in the macrophage protects against atherosclerosis in vivo. J.Biol. Chem., 2001; 276: 36742-36748
  Google Scholar
• 20. Kim Y.J., Lee S.M., Cho H.J., Do H.J., Hong C.H., Shin M.J., KimY.S.: Plasma levels of apolipoprotein E and risk of intracranial arterystenosis in acute ischemic stroke patients. Ann. Nutr. Metab.,2013; 62: 26-31
  Google Scholar
• 21. Krauss R.M.: Lipoprotein subfractions and cardiovascular diseaserisk. Curr. Opin. Lipidol., 2010; 21: 305-311
  Google Scholar
• 22. Krimbou L., Denis M., Haidar B., Carrier M., Marcil M., GenestJ.Jr.: Molecular interactions between apoE and ABCA1: impact onapoE lipidation. J. Lipid Res., 2004; 45: 839-848
  Google Scholar
• 23. Krimbou L., Marcil M., Chiba H., Genest J.Jr.: Structural andfunctional properties of human plasma high density-sized lipoproteincontaining only apoE particles. J. Lipid Res., 2003; 44: 884-892
  Google Scholar
• 24. Krimbou L., Tremblay M., Davignon J., Cohn J.S.: Characterizationof human plasma apolipoprotein E-containing lipoproteins inthe high density lipoprotein size range: focus on pre-β1-LpE, pre-β2-LpE, and α-LpE. J. Lipid Res., 1997; 38: 35-48
  Google Scholar
• 25. Krimbou L., Tremblay M., Jacques H., Davignon J., Cohn J.S.: Invitro factors affecting the concentration of gamma-LpE (γ-LpE) inhuman plasma. J. Lipid Res., 1998; 39: 861-872
  Google Scholar
• 26. Kypreos K.E., Zannis V.I.: Pathway of biogenesis of apolipoproteinE-containing HDL in vivo with the participation of ABCA1 andLCAT. Biochem. J., 2007; 403: 359-367
  Google Scholar
• 27. Lin C.Y., Duan H., Mazzone T.: Apolipoprotein E-dependentcholesterol efflux from macrophages: kinetic study and divergentmechanisms for endogenous versus exogenous apolipoprotein E. J.Lipid Res., 1999; 40: 1618-1627
  Google Scholar
• 28. Lund-Katz S., Phillips M.C.: High density lipoprotein structurefunctionand role in reverse cholesterol transport. Subcell. Biochem.,2010; 51: 183-227
  Google Scholar
• 29. Mahley R.W., Huang Y., Weisgraber K.H.: Putting cholesterolin its place: apoE and reverse cholesterol transport. J. Clin. Invest.,2006; 116: 1226-1229
  Google Scholar
• 30. Mahley R.W., Innerarity T.L., Rall S.C.Jr., Weisgraber K.H.: Plasmalipoproteins: apolipoprotein structure and function. J. Lipid Res.,1984; 25: 1277-1294
  Google Scholar
• 31. Mahley R.W., Rall S.C.Jr.: Apolipoprotein E: far more than a lipidtransport protein. Annu. Rev. Genomics Hum. Genet., 2000; 1: 507-537
  Google Scholar
• 32. Mahley R.W., Weisgraber K.H., Huang Y.: Apolipoprotein E: structuredetermines function, from atherosclerosis to Alzheimer’s diseaseto AIDS. J. Lipid Res., 2009; 50, Suppl.: S183-S188
  Google Scholar
• 33. Matsuura F., Wang N., Chen W., Jiang X.C., Tall A.R.: HDL fromCETP-deficient subjects shows enhanced ability to promote cholesterolefflux from macrophages in an apoE- and ABCG1-dependentpathway. J. Clin. Invest., 2006; 116: 1435-1442
  Google Scholar
• 34. Mendivil C.O., Rimm E.B., Furtado J., Sacks F.M.: Apolipoprotein Ein VLDL and LDL with apolipoprotein C-III is associated with a lowerrisk of coronary heart disease. J. Am. Heart Assoc. 2013; 2: e000130
  Google Scholar
• 35. Mooijaart S.P., Berbee J.F., van Heemst D., Havekes L.M., de CraenA.J., Slagboom P.E., Rensen P.C., Westendorp R.G.: ApoE plasma levelsand risk of cardiovascular mortality in old age. PLoS Med., 2006;3: e176
  Google Scholar
• 36. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R.:ApoE-deficient mice develop lesions of all phases of atherosclerosisthroughout the arterial tree. Arterioscler. Thromb., 1994; 14: 133-140
  Google Scholar
• 37. Nofer J.R.: Rola lipoprotein wysokiej gęstości (HDL) w miażdżycy.W: Kardiologia zapobiegawcza II, red.: M. Naruszewicz. eMKA,Warszawa 2007, 86-121
  Google Scholar
• 38. Ooi E.M., Ng T.W., Watts G.F., Chan D.C., Barrett P.H.: Effect offenofibrate and atorvastatin on VLDL apoE metabolism in men withthe metabolic syndrome. J. Lipid Res., 2012; 53: 2443-2449
  Google Scholar
• 39. Raffai R.L., Loeb S.M., Weisgraber K.H.: Apolipoprotein E promotesthe regression of atherosclerosis independently of loweringplasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol., 2005;25: 436-441
  Google Scholar
• 40. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., FusterV., Goldstein J., Hellerstein M., Jiang X.C., Phillips M.C., Rader D.J.,Remaley A.T., Rothblat G.H., Tall A.R., Yvan-Charvet L.: Cholesterolefflux and atheroprotection: advancing the concept of reverse cholesteroltransport. Circulation, 2012: 125: 1905-1919
  Google Scholar
• 41. Rye K.A., Barter P.J.: Predictive value of different HDL particlesfor the protection against or risk of coronary heart disease. Biochim.Biophys. Acta, 2012; 1821: 473-480
  Google Scholar
• 42. Rye K.A., Bursill C.A., Lambert G., Tabet F., Barter P.J.: The metabolismand anti-atherogenic properties of HDL. J. Lipid Res., 2009;50, Suppl.: S195-S200
  Google Scholar

Full text